BenevolentAI

BenevolentAI was founded in 2013 (originally as Stratified Medical) by the management team of Proximagen who have a track record of building highly successful and disruptive technology companies. They saw the opportunity to forge a union between technology and bioscience using AI in order to accelerate biomedical discoveries. Between Q4 2013 and Q3 2015 the company has conducted four rounds of funding, raising a total of £87.72 million (circa $100m) at a final valuation of $1.781 billion. Lead investors included Woodford Investment Management, Lansdowne Partners, Lundbeck H/S and Upsher Smith Laboratories Inc. In 2014 benevolent.ai signed a licence deal with a US pharmaceutical organisation based on two novel targets for the treatment of Alzheimer’s disease. In September 2016, the company changed its name from Stratified Medical to benevolent.ai to better reflect the wider application of its technology outside of human healthcare and drug discovery.
Type
Private
HQ
Greater London, GB
Founded
2013
Employees
45 (est)+5%
BenevolentAI was founded in 2013 and is headquartered in Greater London, GB

Key People at BenevolentAI

Jackie Hunter

Jackie Hunter

CEO

BenevolentAI Locations

Greater London, GB

BenevolentAI Metrics

BenevolentAI Summary

Founding Date

2013

Total Funding

$100 M

Latest funding size

$100 M

Time since last funding

over 1 year

Investors

We estimate that BenevolentAI's latest funding round in August 2015 was $100 M. In total, BenevolentAI has raised $100 M

BenevolentAI Online Presence

BenevolentAI News

BenevolentAI Company Life

You may also be interested in